Watch GWLL. Know when insiders buy.
One email the day a filing lands. Free.
GWLL
GOLDENWELL BIOTECH, INC.
0.69
+0.00 +0.00%
USD · close Sep 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $68.3MP/E —DIV YIELD —FCF YIELD —REV TTM $55NET INCOME −$282KNET DEBT $150K52W 0.20 – 7.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$35K | −$37K | — | 0.00 | −$47K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $0 | — | — | −$31K | −$18K | — | 0.00 | −$13K | — | — | Aug 14 |
| Q4 2025 · Dec 31 | $55 | — | 21.8% | −$23K | −$200K | — | 0.00 | −$19K | — | — | Jul 1 |
| Q3 2025 · Sep 30 | $0 | — | — | −$26K | −$28K | — | — | −$31K | — | — | Jun 29 |
| Q2 2025 · Jun 30 | $0 | −100.0% | — | −$28K | −$30K | — | — | $59K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $0 | — | — | −$36K | −$39K | — | 0.00 | −$32K | — | — | Aug 14 |
| Q4 2024 · Dec 31 | $0 | −100.0% | — | −$25K | −$27K | — | 0.00 | −$25K | — | — | Jul 1 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$21K | −$23K | — | — | −$21K | — | — | Jun 29 |
| Q2 2024 · Jun 30 | $139 | — | 50.4% | −$48K | −$50K | — | 0.00 | −$48K | — | — | Jun 29 |
| Q1 2024 · Mar 31 | $0 | — | — | −$29K | −$31K | — | 0.00 | −$29K | — | — | Jun 29 |
| Q4 2023 · Dec 31 | $260 | — | 28.1% | −$21K | −$21K | — | — | −$19K | — | — | May 15 |
| Q3 2023 · Sep 30 | $382 | — | 48.7% | −$35K | −$35K | — | — | −$35K | — | — | Nov 26 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $55 | 21.8% | −$113K | −$296K | -539038.2% | 0.00 | −$23K | — | — | — | — |
| FY2024 · to Dec 31 | $139 | 46.0% | −$123K | −$131K | -94602.9% | 0.00 | −$123K | — | — | — | — |
| FY2023 · to Dec 31 | $2K | 36.3% | −$116K | −$117K | -6392.2% | 0.00 | −$113K | — | — | — | — |
| FY2022 · to Dec 31 | $48K | 52.7% | −$985K | −$985K | -2060.9% | — | −$1.1M | — | — | — | — |
| FY2021 · to Dec 31 | $16K | 52.5% | −$118K | −$117K | -732.6% | 0.00 | −$205K | — | — | — | — |
| FY2020 · to Dec 31 | $0 | — | — | −$6K | — | 0.00 | −$6K | — | — | — | — |
Every number comes from GOLDENWELL BIOTECH, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.